Dr. Slain leads the department in continuing our excellence, innovation and leadership to propel our mission forward. His department leadership will align with our Pitt Pharmacy goals driving excellence in education, research, service, and fostering a thriving community, ensuring that our programs continue to excel, and our trainees receive the best education possible. Dr. Slain is a well-respected expert within the infectious diseases and antimicrobial stewardship communities.
Select Peer-reviewed Publications
McCrary LM, Slain D, Shah S, Stoner BJ, Marx AH, Schranz AJ. Emergence of infective endocarditis due to Serratia spp.: Results of a multicenter cohort. Open Forum Infect Dis 2025 (Accepted for publication).
Stover KR, Aldridge HM, Pollan KL, Slain D, Bland CM, Bookstaver PB, Barber KE. The top 10 papers on the treatment of invasive fungal infections, 2018-2023. Ther Adv Infect Dis 2024 Oct 21;11. doi: 10.1177/20499361241290349.
Lambert KV, Demkowicz R, Murray A, Howard C, Slain D. Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales.
Open Forum Infect Dis 2024 Jul 3;11(7):ofae377. doi: 10.1093/ofid/ofae377.
Nissim Y, LaSala PR, Slain D. A Serial passage experiment to assess the development of resistance to ertapenem and meropenem among Enterobacterales. J Antimicrob Chemother 2024; 79 (6): 1463–6. https://doi.org/10.1093/jac/dkae100.
Cimino C, Rivera CG, Pearson JC, Colton B, Slain D, Mahoney MV. Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians. Open Forum Infect Dis 2024; 11(4): ofae128.
https://doi.org/10.1093/ofid/ofae128.
Tsai YV, Bookstaver PB, Kohn J, Justo JA , Childress D, Stramel S, Slain D, Tu P, Wingler JB, Jones BM, Anderson DT, Seddon MM, Cretella DA, Eudy J, Winders H, Antosz K, Bailey P, Al-Hasan MN. The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States. Antimicrob Steward Healthcare Epidemiol 2024, 4, e35, 1–6. doi:10.1017/ash.2024.26.
Barfiel RK, Brown ML, Albrecht B, Barber KE, Bouchard J, Carr A, Chahine E, Cluck D, Covington EW, Deri CR, Durham S, Faulkner-Fennell C, Freeman L, Gauthier T, Gibson G, Green SB, Hobbs A, Jones BM, Jozefczyk C, Marx A, McGee E, McKamey L, Musgrove R, Perez E, Slain D, Stover KR, Turner MS, White C, Bookstaver PB, Bland CM. A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2022. Open Forum Infect Dis 2024;11(3):ofad687.
Slain D. Pharmacist's roles in antimicrobial stewardship: “All hands on deck” [invited editorial]. Am J Health Syst Pharm 2023; 80(21):1523-4. doi: 10.1093/ajhp/zxad218.
Shah S, McCrary M, Schranz AJ, Clarke L, Davis MW, Marx A, Slain D, Stoner BJ, Topal J, Shields RK. Serratia endocarditis: antimicrobial management strategies and clinical outcomes. J Antimicrob Chemother 2023; 78(10):2457-61. doi: 10.1093/jac/dkad254.
Spigelmyer A, Howard C, Rybakov I, Burwell S, Slain D. Impact of clinical pharmacist discharge prescription review on the appropriateness of antibiotic therapy: a retrospective comparison. Int J Clin Pharm 2023; 45(3):769-73. doi:10.1007/s11096-022-01503-7.
Al-Mamun MA, Strock J, Sharker Y, Shawwa K, Schmidt R, Slain D, Sakhuja A, Brothers TN. Evaluating the Medication Regimen Complexity Score as a Predictor of Clinical Outcomes in the Critically Ill. J Clin Med 2022; 11(16), 4705. doi.org/10.3390/jcm11164705.
Slain D, Howard C, Cooper CG. An Antimicrobial Treatment Assessment of Serratia marcescens Bacteremia and Endocarditis. Front Antibiot 2022;1: Article: 942721. doi.org/10.3389/frabi.2022.942721.
Kido K, Slain D, Kamal KM, Lee JC. Adapting the layered learning model to a virtual international exchange program. Curr Pharm Teach Learn 2022 Dec;14(12):1500-1505. doi: 10.1016/j.cptl.2022.10.006.
Hanks CR, Slain D, Kanate AS, Wen S, Cumpston A. Impact of anti-anaerobic antibiotic activity on graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling. Transpl Infect Dis 2021; Aug;23(4):e13676.
Green SB, Stover KR, Barber K, Bouchard JL, Brown ML, Deri CR, Francis BJ, Gauthier TP, Hayes JE, Marx AH, McGee EU, Mediwala K, Musgrove RJ, Slain D, Stramel SA, Bland CM, Bookstaver PB. A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2020. Open Forum Infect Dis 2021 Aug 13;8(9):ofab422. doi: 10.1093/ofid/ofab422.
Slain D, Goad J, Moser LR, Seybert A. Characteristics and Predictors of Patient Care Performed by Clinical Department Chairpersons at U.S. Schools of Pharmacy. J Am Coll Clin Pharm 2021 doi.org/10.1002/jac5.1504.
Slain D. Intravenous Zanamivir: A Viable Option for Critically Ill Patients with Influenza. Ann Pharmacother 2021;55 (6): 760-71.
Slain D, Georgulis A, Dermitt R, Morris L, Colodny SM. Impact of an automatic hospital probiotic protocol on Clostridioides (Clostridium) difficile infection (CDI) rates and CDI antibiotic usage in a community hospital setting. J Infect Prevent 2020;21(2) 72-5.
Amsden JR, Slain D. Dosing Antifungals in Obesity – A Literature Review. Current Fungal Infect Rep 2019;13:1-12.
Schwinghammer TL, Crannage AJ, Boyce EG, Bradley B, Christensen A, Dunnenberger HM, Fravel M, Gurgle H, Hammond DA, Kwon J, Slain D, Wargo KA. The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit. Pharmacotherapy 2016 Nov;36(11):e189-e194.
Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W. Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. Antimicrob Agents Chemother 2016 Jan 11;60:1830-3
Jacobson SM, Slain D. Evaluation of ATLAS Score in Predicting Clinical Cure and Recurrence of Clostridium difficile Infection. Am J Health-Syst Pharm 2015;72 :1871-5.
Slain D, Cleary JD. Isavuconazonium Sulfate: A Novel Antifungal Agent. Curr Fungal Infect Rep 2015; 9(4). doi: 10.1007/s12281-015-0241-2
Guarascio AJ, Slain D. Review of the New Oral Tablet and Intravenous Dosage Forms of Posaconazole. Pharmacotherapy 2015;35:208-19.
Turner RB, Smith CB, Martello JL, Slain D. The role of doxycycline in Clostridium difficile infection acquisition. Ann Pharmacother 2014; 48:772-6.
Dong H, Slain D, Cheng J, Ma W, Liang WF. Eighteen Cases of Liver Injury Following Ingestion of Polygonum multiflorum. Compliment Ther Med 2014;22:70-4.
Stitely M, Sweet M, Slain D, Alons L, Holls C, Hochberg C, Briggs F. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery receiving two differing doses of pre-operative cefazolin. Surg Infections 2013;14:455-9.
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect 2013 Feb;14(1):73-156.
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm 2013;70:195-283
Guarascio AJ, Slain D, Cumpston A. Tacrolimus dose modification in hematopoietic cell transplant recipients following a change in therapy from fluconazole to voriconazole. ISRN Transplantation 2013; 281-285
Ross A, Slain D, Cumpston A, Bryant A, Hamadani M, Craig MD. Evaluation of an alternative Posaconazole prophylaxis regimen in patients with hematologic malignancies receiving stress ulcer prophylaxis. Int J Antimicrob Agents 2012; 40:557-61.
Guarascio AJ, Slain D, McKnight R, Petros K, Parker J, Wilson A, Defazio CM, Sarwari AR.
A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 2013; 35:145–8.
Slain D, Sarwari AR, Petros KO, McKnight R, Sager R, Mullett CJ, Wilson A, Thomas JG, Moffett K, Palmer HC, Dedhia HV. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit. Crit Care Res Pract 2011; (2011): Article ID 416426.
Amsden JR, Slain D. Antifungal Dosing in Obesity: A Review of the Literature. Curr Fungal Infect Rep 2011;5:83-91.
Bryant AM, Slain D, Cumpston A, Craig M. A post marketing evaluation of posaconazole plasma concentrations in neutropenic patients with hematologic malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011;37;266-9.
Gizzi L, Slain D, Hare J, Sager R, Briggs F, Palmer HC. An Assessment of a Safety Enhancement to the Hospital Medication Reconciliation Process for Elderly Patients. Am J Geriatr Pharmacother 2010;8:127-35.
Slain D, Kincaid SE, Dunsworth TS. Discrepancies between home medications listed at hospital admission and reported medical conditions. Am J Geriatric Pharmacotherapy 2008;6(3); 161-6.
Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: A focus on current and future antifungal treatment options. Pharmacotherapy 2007;27:1711-21.
Slain D, Amsden J.R., Khakoo R.A., Fisher M.A., Lalka D., Hobbs G.R. Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers. Pharmacotherapy 2005;25:165-70.
Slain D, Abate M, Hodges BM, Stamatakis MK, Wolak S. Evaluation of an interactive response system to promote active learning and skills development in the doctor of pharmacy curriculum. Am J Pharm Educ 2004;68(5):Article 117.
Stamatakis MK, Schreiber JM, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: Traditional versus a supplemental dosage regimen. Am J Health-Sys Pharm 2003;60:1564-8.
Slain D, Miller K, Khakoo RA, Fisher MA, Wierman T, Jozefczyk K. Infrequent Occurrence of Amphotericin B Lipid Complex (ABLC)-Associated Nephrotoxicity in Various Clinical Settings at a University Hospital.
Clinical Therapeutics 2002; 24:1636-42.
Slain D, Rogers RD, Chapman S, Cleary J. Intravenous hydroxypropyl-b-cyclodextrin formulation of itraconazole: Formulary focus. Ann Pharmacother 2001; 35: 720-9 and 793-4.
Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg S, Lou Y, Moore KHP, Wooley J, Stein DS. Metabolic disposition and pharmacokinetics of [14C]-Amprenavir, a HIV-1 protease inhibitor, administered in a single, oral dose to healthy subjects. J Clin Pharmacol 2001; 41: 386-96.
Slain D, Pakyz A, Israel D, Monroe SG, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000;20:898-907.
Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999;19 (3):306-23.
